問卷

TPIDB > Study Site

Study Site



Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

  • 2,634

    Total Beds

  • 1,095

    Total Doctors

  • jmventcc@cgmh.org.tw
  • CHANG-CHIEN, CHIA-MIN
  • 07-7317123#6416
  • 833Kaohsiung CityKaohsiung NiaosongNo. 123, Dapi Rd., Niaosong Dist., Kaohsiung City 833 , Taiwan (R.O.C.)

篩選

List

1457Cases

2012-05-01 - 2013-08-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
15Sites

Terminated15Sites

2011-06-01 - 2013-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Study ended9Sites

2010-08-01 - 2020-07-31

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Terminated16Sites

2017-08-01 - 2020-04-30

Phase III

A multinational, multi-center, randomized, double-blind, active comparator, phase III clinical trial to evaluate the efficacy and safety of donepezil transdermal patch in patients with Alzheimer’s disease
  • Condition/Disease

    mild to moderate Alzheimer's disease patient

  • Test Drug

    Donepezil transdermal patch

Participate Sites
12Sites

Terminated12Sites

2017-08-01 - 2022-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated7Sites

2015-02-25 - 2025-12-31

Phase III

A PHASE III PROSPECTIVE DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ADJUVANT MEDI4736 IN COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER
  • Condition/Disease

    COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER

  • Test Drug

    MEDI4736

Participate Sites
13Sites

Not yet recruiting2Sites

Recruiting3Sites

Terminated8Sites

2022-06-01 - 2026-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2019-12-01 - 2022-12-31

Phase I

A Phase I Open-Label Study of the Safety and Tolerability of ATG-019, a Dual Inhibitor of PAK4 and NAMPT, in patients with Advanced Solid Tumors or Non-Hodgkin's Lymphoma.
  • Condition/Disease

    Solid Tumor/Non-Hodgkin's Lymphoma

  • Test Drug

    ATG-019

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites